Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 9:34 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 11,586 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: CHRONIC DISEASE Clear all
Completed Phase 1 Interventional

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

NCT02240719
View directory record Official record
Conditions
Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia, Multiple Myeloma
Interventions
everolimus, bendamustine hydrochloride
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Nov 9, 2026, 9:34 AM EST
Completed Not applicable Interventional

Audio-visual Stimulation: Sleep Dose Response

NCT03569865
View directory record Official record
Conditions
Insomnia Chronic, Osteoarthritis, Pain, Chronic
Interventions
Audiovisual Stimulation
Device
Lead sponsor
University of Washington
Other
Eligibility
60 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Nov 9, 2026, 9:34 AM EST
Completed Not applicable Interventional

Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema

NCT00475007
View directory record Official record
Conditions
Emphysema, COPD
Interventions
IBV® Valve System
Device
Lead sponsor
Olympus Corporation of the Americas
Industry
Eligibility
40 Years to 74 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
34
States / cities
Birmingham, Alabama • Los Angeles, California • Mission Viejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Nov 9, 2026, 9:34 AM EST
Completed Phase 2 Interventional Results available

Tadalafil for Pulmonary Hypertension Due to Chronic Lung Disease

NCT01862536
View directory record Official record
Conditions
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease (COPD)
Interventions
Tadalafil, placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 85 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2019
U.S. locations
5
States / cities
West Los Angeles, California • Denver, Colorado • Decatur, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2021 · Synced Nov 9, 2026, 9:34 AM EST
Recruiting No phase listed Observational Accepts healthy volunteers

Site and Mechanism(s) of Expiratory Airflow Limitation in COPD, Emphysema and Asthma-COPD Overlap

NCT03263130
View directory record Official record
Conditions
COPD, Emphysema, Asthma COPD Overlap, Emphysema
Interventions
As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap
Other
Lead sponsor
Gelb, Arthur F., M.D.
Individual
Eligibility
30 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
Lakewood, California
Source: ClinicalTrials.gov public record
Updated Oct 27, 2023 · Synced Nov 9, 2026, 9:34 AM EST
Completed No phase listed Observational

Biorepository of Biospecimen Samples in Matched Healthy Control Participants and Participants Diagnosed With Diabetic Kidney Disease, Chronic Kidney Disease, or Type 2 Diabetes

NCT05631119
View directory record Official record
Conditions
Diabetic Kidney Disease, Diabetes Type 2, Chronic Kidney Diseases, Healthy
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 85 Years
Enrollment
40 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Woburn, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 3, 2023 · Synced Nov 9, 2026, 9:34 AM EST
Active, not recruiting Phase 1 Interventional

Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets

NCT05618028
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, B Cell Malignancies, Non-Hodgkin's Lymphoma
Interventions
ABBV-525
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
Los Angeles, California • New Haven, Connecticut • Miami Beach, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Nov 9, 2026, 9:34 AM EST
Recruiting No phase listed Observational

Predictive Biomarker for Endoscopic Therapy in Chronic Pancreatitis

NCT06267365
View directory record Official record
Conditions
Chronic Pancreatitis
Interventions
Not listed
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Nov 9, 2026, 9:34 AM EST
Active, not recruiting Phase 1Phase 2 Interventional

A Study of Nemtabrutinib (MK-1026) in Participants With Relapsed or Refractory Hematologic Malignancies (ARQ 531-101/MK-1026-001)

NCT03162536
View directory record Official record
Conditions
Lymphoma, B-Cell, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Diffuse Large B Cell Lymphoma, Richter's Transformation, Follicular Lymphoma, Marginal Zone Lymphoma
Interventions
Nemtabrutinib
Drug
Lead sponsor
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
10
States / cities
Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Nov 9, 2026, 9:34 AM EST
Withdrawn Not applicable Interventional

TNF-alpha Inhibition in CRPS: A Randomized Controlled Trial

NCT02031211
View directory record Official record
Conditions
CRPS, Chronic Regional Pain Syndrome
Interventions
Etanercept, Placebo
Drug
Lead sponsor
Stanford University
Other
Eligibility
10 Years to 17 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 14, 2016 · Synced Nov 9, 2026, 9:34 AM EST
Completed No phase listed Observational Accepts healthy volunteers

Cough Reflex Sensitivity and Bronchial Hyper-responsiveness

NCT01777867
View directory record Official record
Conditions
Gastroesophageal Reflux Disease, Chronic Cough, Broncho-hyperreactivity
Interventions
Cough Reflex Sensitivity, Methacholine Challenge
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 60 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Feb 17, 2017 · Synced Nov 9, 2026, 9:34 AM EST
Completed Not applicable Interventional Accepts healthy volunteers

Embodiment in Virtual Reality as a Telemedicine Digital Therapeutic for the Treatment of Chronic Shoulder Pain

NCT05375500
View directory record Official record
Conditions
Chronic Pain, Low Back Pain, Shoulder Pain
Interventions
telemedicine digital therapeutic
Device
Lead sponsor
Karuna Labs Inc.
Industry
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Los Gatos, California
Source: ClinicalTrials.gov public record
Updated May 16, 2022 · Synced Nov 9, 2026, 9:34 AM EST
Not listed Phase 1 Interventional

Study of XTL6865 in Patients With Chronic Hepatitis C Virus Infection

NCT00300807
View directory record Official record
Conditions
Hepatitis C
Interventions
XTL 6865
Drug
Lead sponsor
XTL Biopharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
4
States / cities
Indianapolis, Indiana • New York, New York • Chapel Hill, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2007 · Synced Nov 9, 2026, 9:34 AM EST
Completed No phase listed Observational

Voices From the Black Community: Hepatitis C Research Participation

NCT04202081
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
21 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2020 · Synced Nov 9, 2026, 9:34 AM EST
Active, not recruiting Phase 3 Interventional

Allogeneic ABCB5-positive Dermal Mesenchymal Stromal Cells for Treatment of Therapy-resistant CVU (Phase III)

NCT06489028
View directory record Official record
Conditions
Venous Leg Ulcer
Interventions
allo-APZ2-CVU, Placebo
Drug
Lead sponsor
RHEACELL GmbH & Co. KG
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
4
States / cities
Hialeah, Florida • Miami, Florida • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Nov 9, 2026, 9:34 AM EST
Completed Not applicable Interventional Results available

Home-Based Intervention for Chronic Pain in Adults With Sickle Cell Disease

NCT04906707
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
EaseVRx, Audio-only version of EaseVRx
Device · Behavioral
Lead sponsor
Emory University
Other
Eligibility
18 Years to 50 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 20, 2025 · Synced Nov 9, 2026, 9:34 AM EST
Completed Phase 3 Interventional Results available

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

NCT00446511
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan, Enalapril, placebo matched to enalapril, placebo matched to valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Nov 9, 2026, 9:34 AM EST
Not listed Not applicable Interventional Accepts healthy volunteers

TaiChi-DTx for Treating Long Covid Symptoms

NCT05419219
View directory record Official record
Conditions
Fatigue, Dyspnea, Cognitive Impairment, Muscle Pain
Interventions
the multi-domain Tai Chi Digital therapy Software Application
Device
Lead sponsor
Tim Shi
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Ellicott City, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 15, 2023 · Synced Nov 9, 2026, 9:34 AM EST
Completed Phase 1 Interventional

A Study of BNC105P Combined With Ibrutinib

NCT03454165
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia
Interventions
BNC105P, Ibrutinib
Combination Product
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Jan 4, 2023 · Synced Nov 9, 2026, 9:34 AM EST
Terminated Phase 1 Interventional

Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT

NCT02728700
View directory record Official record
Conditions
Adult Hodgkin Lymphoma, Adult Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Childhood Hodgkin Lymphoma, Childhood Myelodysplastic Syndrome, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelofibrosis, Primary Myelofibrosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Non-Hodgkin Lymphoma, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Non-Hodgkin Lymphoma
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Laboratory Biomarker Analysis, Mycophenolate Mofetil, Sirolimus
Procedure · Other · Drug
Lead sponsor
Stanford University
Other
Eligibility
3 Years to 30 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2018 · Synced Nov 9, 2026, 9:34 AM EST
Completed Not applicable Interventional Results available

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

NCT01872819
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions
antitumor drug screening assay, chemotherapy, biological therapy
Other · Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Nov 9, 2026, 9:34 AM EST
Completed Phase 1 Interventional

A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma

NCT01209130
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia
Interventions
DCDT2980S, rituximab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
9
States / cities
Stanford, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 9, 2026, 9:34 AM EST
Completed Not applicable Interventional Results available

APOL1 Genetic Testing Program for Living Donors

NCT04910867
View directory record Official record
Conditions
Chronic Kidney Diseases, Apolipoprotein L1, Kidney Transplantation
Interventions
Components of Genetic Counseling, APOL1 genetic testing, EHR integration
Behavioral · Diagnostic Test · Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 9, 2026, 9:34 AM EST
Completed Phase 1Phase 2 Interventional Results available

Ofatumumab as Primary Therapy of Chronic Graft Versus Host Disease

NCT01680965
View directory record Official record
Conditions
Chronic Graft Versus Host Disease
Interventions
Ofatumumab
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
4
States / cities
Phoenix, Arizona • Tampa, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2022 · Synced Nov 9, 2026, 9:34 AM EST